Shifting demands, price and portfolio pressures are pushing pharma manufacturers to fast-track innovation Precision medicine is having a direct impact on manufacturing facilities from complexity and activity perspectives: Pharma companies are now forced to think in terms of manufacturing medicine for a few thousand patients instead of the traditional mass volume manufacturing. With the health regulators taking an encouraging stance towards innovations in manufacturing, the stage is set for Pharmaceutical Manufacturers to adopt innovative manufacturing philosophies such as Continuous Manufacturing, 3D Bioprinting and the associated technological artifacts e.g. Single Use Systems.

There is no single panacea for healthcare cost burden that is increasing globally/ Manufacturing is also neither 'the' growth driver nor the biggest 'cost sink' for a Pharma company; however, it certainly is a very important frontier for any bio/pharma company to stay on the competitive edge. At the same time, it is in the interest of all healthcare stakeholders manufacturing of essential medicines is reliable, consistent and cost-effective. The upcoming technologies promise to deliver on those requirements effectively and hopefully, cost-effectively